Know Cancer

forgot password

A Phase II Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2
18 Years
Open (Enrolling)
Extensive-Stage Small Cell Lung Cancer

Thank you

Trial Information

A Phase II Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Inclusion Criteria:

1. Cytologically and/or histologically confirmed small-cell lung cancer with extensive
stage disease.

2. Measurable or evaluable disease per RECIST criteria version 1.1.

3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1.

4. Left ventricular ejection fraction (LVEF) ≥50% by echocardiogram (ECHO) or multiple
gated acquisition scan (MUGA).

5. QTc interval of ≤450 msec. on ECG.

6. Adequate organ function, including the following:

- ANC ≥1500 cells/micro liter

- Platelet count ≥100,000 cells/micro liter

- Hemoglobin ≥9 g/dL

- Total bilirubin ≤1.5 x ULN; AST/ALT ≤2.5 x ULN, (except if due to hepatic
metastases, then ≤5 x ULN)

- Serum creatinine ≤1.5 x ULN

7. Patients must be able to receive growth factors (G-CSF).

8. Women of childbearing potential must have a negative serum or urine pregnancy test
performed ≤ 7 days prior to start of treatment. Women of childbearing potential or
men with partners of childbearing potential must use effective birth control measures
during treatment. If a woman becomes pregnant or suspects she is pregnant while
participating in this study, she must agree to inform her treating physician

9. Patients ≥18 years of age.

10. Patients must be accessible for treatment and follow-up.

11. Patients must be able to understand the investigational nature of this study and give
written informed consent prior to study entry.

Exclusion Criteria:

1. Previous treatment for limited-stage SCLC.

2. Previous chemotherapy or radiation therapy for SCLC (unless radiation was
administered for brain metastases).

3. Active brain metastases. Patients with treated brain metastases are eligible, if (1)
radiation therapy was completed ≥ 21 days prior to first dose of amrubicin; (2)
follow-up scan shows no disease progression; an absence of neurologic symptoms and
(3) patient does not require steroids.

4. Mixed small cell/non-small cell tumors or other neuroendocrine lung cancers.

5. Women who are pregnant or breastfeeding.

6. Suspected, diffuse idiopathic interstitial lung disease or pulmonary fibrosis.

7. Patients with New York Heart Association (NYHA) class II or greater congestive heart
failure (CHF).

8. Any of the following ≤6 months prior to starting study treatment:

- myocardial infarction;

- severe unstable angina;

- ongoing cardiac dysrhythmia.

9. Family history of idiopathic cardiomyopathy or uncontrolled heart arrhythmia.

10. Treatment for other invasive cancers during the previous 5 years, or the presence of
any active invasive cancer of any type (with the exception of non-melanoma skin

11. Uncontrolled hypertension (i.e., blood pressure >150/90 mmHg that cannot be
controlled with standard anti-hypertensive agents).

12. Major surgical procedure or significant traumatic injury ≤ 28 days of study

13. History of seropositive HIV or patients who are receiving immunosuppressive
medications that would in the opinion of the investigator increase the risk of the
serious neutropenic complications.

14. Concurrent severe, intercurrent illness including, but not limited to, ongoing or
active infection, or psychiatric illness/social situations that would limit
compliance with study requirements.

15. Any condition that would prevent patient comprehension of the nature of, and risk
associated with, the study.

16. Use of any non-approved or investigational agent ≤30 days prior to administration of
the first dose of study drug. Patients may not receive any other investigational or
anti-cancer treatments while participating in this study.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess the 1-year survival of patients with ES-SCLC when receiving amrubicin and carboplatin in combination.

Outcome Time Frame:

36 months

Safety Issue:


Principal Investigator

David R Spigel, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

December 2009

Completion Date:

December 2016

Related Keywords:

  • Extensive-Stage Small Cell Lung Cancer
  • SCLC
  • Amrubicin
  • Carboplatin
  • Pegfilgrastim
  • Neulasta
  • Lung Neoplasms
  • Small Cell Lung Carcinoma



Florida Hospital Cancer Institute Orlando, Florida  32804
Northeast Arkansas Clinic Jonesboro, Arkansas  72401-3125
Florida Cancer Specialists Fort Myers, Florida  33901
Research Medical Center Kansas City, Missouri  64132
South Carolina Oncology Associates, PA Columbia, South Carolina  29210
Family Cancer Center Collierville, Tennessee  38017
Virginia Cancer Institute Richmond, Virginia  23230
Medical Oncology Associates of Augusta Augusta, Georgia  30901
Peninsula Cancer Institute Newport News, Virginia  23601
Center for Cancer and Blood Disorders Bethesda, Maryland  20817
Grand Rapids Clinical Oncology Program Grand Rapids, Michigan  49503
Tennessee Oncology, PLLC Clarksville, Tennessee  37043
Oncology Hematology Care Cincinnati, Ohio  45242
Watson Clinic Center for Cancer Care and Research Lakeland, Florida  33805
Baptist Hospital East Louisville, Kentucky  40207
Norton Cancer Institute Louisville, Kentucky  40207
Hematology Oncology Clinic, LLP Baton Rouge, Louisiana  70809
National Capital Clinical Research Consortium Bethesda, Maryland  20817
Chattanooga Oncology Hematology Associates Chattanooga, Tennessee  37404
Nebraska Methodist Cancer Center Omaha, Nebraska  68114